Vitrosens Biotechnology

Vitrosens Biotechnology is a commercial-stage, private IVD company with a diversified product portfolio spanning lateral flow rapid tests, immunofluorescence (FIA) platforms, and molecular diagnostics (PCR, extraction). Its strategic focus on both human and veterinary diagnostics provides two significant revenue streams and leverages shared technological platforms. Backed by certified manufacturing and R&D, the company serves over 70 countries, aiming to become a global IVD leader from its base in Turkey. The business model is firmly in the Diagnostics category, generating revenue through the sale of instruments, consumables, and test kits.

Integrated diagnostics platform encompassing lateral flow rapid tests, quantitative immunofluorescence assay (FIA) point-of-care systems, and a full molecular diagnostics suite (automated nucleic acid extraction, liquid/lyophilized PCR reagents, real-time PCR instruments). Technology is applied across both human and veterinary health.

Vitrosens operates in the highly competitive global IVD market, competing against giants like Abbott, Roche, and Siemens in human health, and IDEXX and Zoetis in animal health. Its competitive edge lies in its agility, cost-effectiveness, dual human/veterinary focus, and MDSAP-certified quality from a strategic location serving emerging markets.